Projects / Programmes
Prognostic value of uPA, PAI 1 and PAI 2 in solid tumors
Code |
Science |
Field |
Subfield |
3.04.00 |
Medical sciences |
Oncology |
|
Code |
Science |
Field |
B007 |
Biomedical sciences |
Medicine (human and vertebrates) |
B200 |
Biomedical sciences |
Cytology, oncology, cancerology |
plasminogen activator, plasminogen activator inhibitors, prognosis, breast cancer, bladder cancer
Organisations (3)
, Researchers (17)
0302 Institute of Oncology Ljubljana
0381 University of Ljubljana, Faculty of Medicine
no. |
Code |
Name and surname |
Research area |
Role |
Period |
No. of publicationsNo. of publications |
1. |
07187 |
PhD Andrej Mašera |
Oncology |
Researcher |
1998 - 1999 |
134 |
2. |
07228 |
PhD Zdenka Ovčak |
Oncology |
Researcher |
1998 - 1999 |
78 |
1538 University of Ljubljana, Faculty of Electrical Engineering
no. |
Code |
Name and surname |
Research area |
Role |
Period |
No. of publicationsNo. of publications |
1. |
05071 |
PhD Ankica Babič |
Computer science and informatics |
Researcher |
1998 - 1999 |
104 |
Abstract
The prognosis of cancer patients depends largely on the ability of cancer cells to invade the surrounding tissue and to metastasize. These processes are influenced by tumor-associated proteases among which serine proteases and their inhibitors may play a central role. The aim of our study is to determine the content of serine protease uPA and its inhibitors PAI 1 and PAI 2, in primary tumors of the breast and urinary bladder, and to establish their prognostic value. It is hoped that the results of our study could be used for a more rational treatment planning in patients with primary cancers of the breast and urinary bladder, thus improving their survival.